Radiotherapy improves progression-free survival in oligometastatic NSCLC

The SARON trial found that adding consolidation radiotherapy to systemic therapy improved local disease control but did not extend overall survival.

Adding consolidation radiotherapy to first-line systemic anticancer therapy significantly improved progression-free survival and reduced progression at sites of disease present at diagnosis. In the randomized phase II SARON trial, median progression-free survival was 13.9 months with systemic therapy plus radiotherapy compared with 8.9 months with systemic therapy alone. This represents an approximately 36% reduction in the hazard of progression or death.

The effect on local disease control was significant. Progression at sites of initial disease occurred in 13.0% of patients receiving consolidation radiotherapy versus 39.5% with systemic therapy alone. However, the improvement in progression-free survival did not translate into longer overall survival. Median overall survival was 31.0 months for the radiotherapy group versus 28.0 months for those receiving systemic therapy alone.

The SARON trial was a multicenter study conducted across 22 centres in the United Kingdom. It enrolled 140 patients with non-small cell lung cancer (NSCLC) without targetable driver alterations and one to five synchronous metastases. Patients initially received approximately six to eight weeks of systemic anticancer therapy.

Of the 140 patients, 70 were assigned to systemic therapy alone and 70 to systemic therapy followed by consolidation radiotherapy. The radiotherapy strategy included treating the primary lung tumor with conventional radical radiotherapy or stereotactic ablative radiotherapy (SABR), while metastatic sites received SABR or stereotactic radiosurgery.

Enrollment ran from 2016 through 2023. During this period, 40% of patients received chemotherapy, 15% received immunotherapy, and 45% received combined chemoimmunotherapy. The trial results were presented at the ESMO Congress 2026.

Key facts

  • Median progression-free survival was 13.9 months with systemic therapy plus radiotherapy compared to 8.9 months with systemic therapy alone.
  • Progression at initial disease sites fell to 13.0% with consolidation radiotherapy compared to 39.5% with systemic therapy alone.
  • Median overall survival was 31.0 months with radiotherapy versus 28.0 months with systemic therapy alone.

Three perspectives

Neutral

The SARON trial shows that while consolidation radiotherapy improves local disease control and progression-free survival, it does not extend overall survival for these patients.

Positive

Adding consolidation radiotherapy significantly improved progression-free survival and substantially reduced progression at the sites of disease already present at diagnosis.

Negative

The improvement in progression-free survival did not translate into longer overall survival.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

All sections

Edition